

Source

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Trastuzumab F(ab')₂.

Isotype

IgG1/kappa

Specificity

Recognizes Trastuzumab specifically, no cross reactivity with other humanized antibodies.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.


Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

- This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
 - -70°C for 12 months under sterile conditions after reconstitution.


SDS-PAGE



Anti-Trastuzumab Antibodies (recommended for PK/PD) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.


Bioactivity-ELISA

Determination of Anti-Trastuzumab Antibodies Specificity




Demonstration of the specificity of Anti-Trastuzumab Antibodies (Cat. No. TRB-Y1) to the trastuzumab.

Anti-Trastuzumab Antibodies—Inhibition ELISA



Measured by its neutralizing ability in a functional ELISA. Immobilized Trastuzumab at 0.5 μg/mL (100 μL/well) can bind pre-mixed Anti-Trastuzumab Antibodies (Cat. No. TRB-Y1) and Biotinylated Human Her2, His,Avitag (Cat. No. HE2-H82E2) with a inhibition rate of 80%.

Bioactivity-SPR



Anti-Trastuzumab Antibodies (mouse IgG1, Cat. No. TRB-Y1) captured on CM5 chip via anti-mouse antibodies surface, can bind human trastuzumab with an affinity constant of 0.296 nM.

Background

Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay ($K_d = 5 \text{ nM}$) to the extracellular domain of the human epidermal growth factor receptor protein.

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.